Improved survival modeling in cancer research using a reduced piecewise exponential approach
Abstract
Statistical models for survival data are typically nonparametric, for example, the Kaplan–Meier curve. Parametric survival modeling, such as exponential modeling, however, can reveal additional insights and be more efficient than nonparametric alternatives. A major constraint of the existing exponential models is the lack of flexibility due to distribution assumptions. A flexible and parsimonious piecewise exponential model is presented to best use the exponential models for arbitrary survival data. This model identifies shifts in the failure rate over time based on an exact likelihood ratio test, a backward elimination procedure, and an optional presumed order restriction on the hazard rate. Such modeling provides a descriptive tool in understanding the patient survival in addition to the Kaplan–Meier curve. This approach is compared with alternative survival models in simulation examples and illustrated in clinical studies. Copyright © 2013 John Wiley & Sons, Ltd.
Citing Literature
Number of times cited according to CrossRef: 11
- Jason J.Z. Liao, Guanghan Frank Liu, A flexible parametric survival model for fitting time to event data in clinical trials, Pharmaceutical Statistics, 10.1002/pst.1947, 18, 5, (555-567), (2019).
- Theodoros Moysiadis, Panagiotis Baliakas, Davide Rossi, Mark Catherwood, Jonathan C. Strefford, Julio Delgado, Achilles Anagnostopoulos, Chrysoula Belessi, Niki Stavroyianni, Sarka Pospisilova, David Oscier, Gianluca Gaidano, Elias Campo, Richard Rosenquist, Paolo Ghia, Kostas Stamatopoulos, Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen b-receptors, Leukemia, 10.1038/s41375-018-0322-7, (2019).
- Daniel T. Lythgoe, Marta Garcia-Fiñana, Trevor F. Cox, Latent Class Modeling with A Time-To-Event Distal Outcome: A Comparison of One, Two and Three-Step Approaches, Structural Equation Modeling: A Multidisciplinary Journal, 10.1080/10705511.2018.1495081, 26, 1, (51-65), (2018).
- Thiago Rezende dos Santos, Dani Gamerman, Glaura da Conceicao Franco, Reliability Analysis via Non-Gaussian State-Space Models, IEEE Transactions on Reliability, 10.1109/TR.2017.2670142, 66, 2, (309-318), (2017).
- Antje Hoering, Brian Durie, Hongwei Wang, John Crowley, End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma, Future Oncology, 10.2217/fon-2016-0504, 13, 13, (1181-1193), (2017).
- Hansapani Rodrigo, Chris P. Tsokos, Artificial Neural Network Model for Predicting Lung Cancer Survival, Journal of Data Analysis and Information Processing, 10.4236/jdaip.2017.51003, 05, 01, (33-47), (2017).
- Gang Han, Michael J. Schell, Heping Zhang, Daniel Zelterman, Lajos Pusztai, Kerin Adelson, Christos Hatzis, Testing violations of the exponential assumption in cancer clinical trials with survival endpoints, Biometrics, 10.1111/biom.12590, 73, 2, (687-695), (2016).
- Kerin Adelson, Bhuvaneswari Ramaswamy, Joseph A Sparano, Paul J Christos, John J Wright, George Raptis, Gang Han, Miguel Villalona-Calero, Cynthia X Ma, Dawn Hershman, Joseph Baar, Paula Klein, Tessa Cigler, G Thomas Budd, Yelena Novik, Antoinette R Tan, Susan Tannenbaum, Anupama Goel, Ellis Levine, Charles L Shapiro, Eleni Andreopoulou, Michael Naughton, Kevin Kalinsky, Sam Waxman, Doris Germain, Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial, npj Breast Cancer, 10.1038/npjbcancer.2016.37, 2, 1, (2016).
- Michael J. Crowther, Paul C. Lambert, A general framework for parametric survival analysis, Statistics in Medicine, 10.1002/sim.6300, 33, 30, (5280-5297), (2014).
- Yong Ma, Yinglei Lai, John M. Lachin, Identifying Change Points in a Covariate Effect on Time-to-Event Analysis with Reduced Isotonic Regression, PLoS ONE, 10.1371/journal.pone.0113948, 9, 12, (e113948), (2014).
- Gang Han, Designing historical control studies with survival endpoints using exact statistical inference, Pharmaceutical Statistics, 10.1002/pst.2050, 0, 0, (undefined).
